Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DS-7309
- Development stage
- Phase 1
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DS-7309 is an orally administered small molecule drug developed by Daiichi Sankyo as a glucokinase activator for the treatment of type 2 diabetes mellitus. Glucokinase activators work by stimulating glucokinase, an enzyme that plays a key role in glucose metabolism in pancreatic beta cells and the liver, thereby enhancing glucose utilization and lowering blood sugar levels. Clinical development included phase I trials to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and subjects with type 2 diabetes mellitus. Development for this indication was discontinued after phase I[1][2][4].
02
Targets
GCK (Glucokinase)
Beyond the preview
Go deeper on DS-7309.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DS-7309.